Anti-TRIM29 antibody [ABM43D2]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The tripartite motif-containing protein 29 (TRIM29) also known as ATDC is a protein with a molecular mass of approximately 66 kDa. TRIM29 is part of the TRIM family characterized by its RING finger motif B-box type 1 and 2 domains and a coiled-coil region which are significant for its involvement in ubiquitination processes. Researchers have found TRIM29 expression largely in epithelial tissues exhibiting varied levels of expression depending on tissue type.

Biological function summary

TRIM29 functions as an essential regulator of DNA damage responses and cellular proliferation. It is not found as part of any larger protein complex but interacts with various other proteins to carry out its function. TRIM29 can influence the activity of key molecules involved in DNA repair particularly through its interaction with DNA-dependent protein kinase catalytic subunit (DNA-PKcs) which enhances cell survival after genotoxic stress. It participates in ensuring proper functioning of cell cycle checkpoints and modulation of apoptosis.

Pathways

TRIM29 participates in the DNA damage response pathway and the WNT signaling pathway. It interacts with proteins such as β-catenin which influences the transcriptional regulation of target genes involved in cell proliferation. Through these interactions TRIM29 influences cellular responses to DNA damage and the regulation of cell growth linking it to critical pathways that maintain genomic stability and cell integrity.

Associated diseases and disorders

Aberrant TRIM29 expression correlates with various cancers including breast and colorectal cancers. In breast cancer TRIM29 affects the pathways involving p53 a known tumor suppressor protein. In colorectal cancer its overexpression is associated with enhanced cancer cell proliferation and survival often in conjunction with KRAS mutations. TRIM29's regulatory role in these pathways highlights its potential as a biomarker and a therapeutic target in oncology.